Stockscreener 앱 받기
11.49
1.96%
-0.23
시간 외 거래:
11.71
0.22
+1.91%
전일 마감가:
$11.72
열려 있는:
$11.59
하루 거래량:
681.93K
Relative Volume:
0.66
시가총액:
$359.52M
수익:
$17.50M
순이익/손실:
$-58.88M
주가수익비율:
-5.452
EPS:
-2.1075
순현금흐름:
$-46.16M
1주 성능:
-2.79%
1개월 성능:
-4.65%
6개월 성능:
-72.82%
1년 성능:
-54.98%
1일 변동 폭
$11.22
$11.88
1주일 범위
$11.22
$12.70
52주 변동 폭
$11.21
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
명칭
Lenz Therapeutics Inc
전화
858-925-7000
주소
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
11.49 | 366.72M | 17.50M | -58.88M | -46.16M | -2.1075 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2025-03-18 | 개시 | TD Cowen | Buy |
| 2024-09-27 | 개시 | Raymond James | Outperform |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-04-10 | 개시 | Citigroup | Buy |
| 2024-03-27 | 개시 | Piper Sandler | Overweight |
| 2023-02-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-25 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-01-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-14 | 개시 | BTIG Research | Buy |
| 2022-03-22 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | 개시 | Morgan Stanley | Overweight |
| 2021-07-20 | 개시 | SVB Leerink | Outperform |
모두보기
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
Can LENZ Therapeutics Inc. be the next market leader2026 Big Picture & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026 - The Manila Times
IPO Launch: Is LENZ Therapeutics Inc affected by consumer sentimentMarket Rally & AI Driven Stock Movement Reports - baoquankhu1.vn
693,044 Shares in LENZ Therapeutics, Inc. $LENZ Acquired by First Light Asset Management LLC - MarketBeat
LENZ Therapeutics, Inc. $LENZ is Ally Bridge Group NY LLC's 7th Largest Position - MarketBeat
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia - marketscreener.com
Performance Recap: Can LENZ Therapeutics Inc reach all time highs this year2026 Historical Comparison & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
LENZ Therapeutics Projected to Post Earnings on WednesdayDel Mar Today - National Today
William Blair Maintains Outperform on LENZ Therapeutics, Inc (LENZ) March 10 2026 - Meyka
LENZ Therapeutics (LENZ) Projected to Post Earnings on Wednesday - MarketBeat
LENZ submits marketing application for presbyopia drug in Europe - Investing.com South Africa
William Blair reiterates Lenz Therapeutics stock rating on VIZZ potential By Investing.com - Investing.com Canada
LENZ submits marketing application for presbyopia drug in Europe By Investing.com - Investing.com Australia
LENZ: Rapidly growing prescriber base and strong refill rates highlight successful launch momentum - TradingView
LENZ: Strong launch for a new presbyopia eye drop, with rapid adoption and robust safety profile - TradingView
William Blair reiterates Lenz Therapeutics stock rating on VIZZ potential - Investing.com
LENZ Therapeutics Submits Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia - marketscreener.com
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia - LENZ Therapeutics
New eye drop for age-related blurry vision heads to EU review - Stock Titan
Tyro Capital Management LLC Makes New $4.69 Million Investment in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Lenz plunges after adverse event report on eye therapy - MSN
Aug Sentiment: Is LENZ Therapeutics Inc a strong candidate for buy and hold2026 Price Momentum & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Market Pulse: Why is LENZ Therapeutics Inc stock going upMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Presbyopia Pipeline 2026: 10+ Companies, 10+ Emerging Therapies, and 3 Key FDA NDA Milestones Driving the Future of Vision Care, analyses DelveInsight - StreetInsider
LENZ: Strong launch momentum for a new presbyopia eye drop, with robust efficacy and market uptake - TradingView
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Should You Buy LENZ Therapeutics Inc (LENZ) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
LENZ Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Bearish Setup: What are LENZ Therapeutics Incs recent SEC filings showingMarket Activity Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
LENZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Versant Venture Management LLC Buys Shares of 2,656,888 LENZ Therapeutics, Inc. $LENZ - MarketBeat
LENZ Therapeutics to Present at Upcoming Investor Conferences - LENZ Therapeutics
Presbyopia eye-drop firm LENZ lines up two investor conferences - Stock Titan
Risk Check: Can LENZ Therapeutics Inc sustain its profitabilityGold Moves & High Accuracy Swing Trade Signals - baoquankhu1.vn
LENZ Therapeutics (NASDAQ:LENZ) Rating Lowered to Sell at Wall Street Zen - MarketBeat
What’s the beta of LENZ Therapeutics Inc. stockQuarterly Profit Review & Breakout Confirmation Trade Signals - mfd.ru
Breakout Move: What are LENZ Therapeutics Incs recent SEC filings showingWeekly Gains Summary & High Yield Equity Trading Tips - baoquankhu1.vn
Weekly Earnings: Can LENZ Therapeutics Inc reach all time highs this yearMarket Trend Review & Safe Entry Zone Tips - baoquankhu1.vn
LENZ Therapeutics, Inc. $LENZ Shares Acquired by Skandinaviska Enskilda Banken AB publ - MarketBeat
Ridgeback exits Lenz Therapeutics (LENZ) with 0% reported ownership stake - Stock Titan
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Decreases By 16.8% - MarketBeat
How LENZ Therapeutics Inc. stock compares to market leaders2025 EndofYear Setup & Fast Gain Stock Trading Tips - mfd.ru
LENZ Therapeutics (LENZ) Stock Analysis: Eyeing A 295% Upside In The Biotech Arena - DirectorsTalk Interviews
Analyst Upgrade: Can LENZ Therapeutics Inc disrupt its industryNew Guidance & Consistent Income Trade Recommendations - baoquankhu1.vn
Why is LENZ Therapeutics Inc. stock going upWeekly Stock Report & Reliable Price Action Trade Plans - mfd.ru
Fund Flows: What is the cash position of LENZ Therapeutics IncEarnings Recap Report & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Can LENZ Therapeutics Inc. benefit from deglobalizationJuly 2025 Momentum & Low Risk Growth Stock Ideas - mfd.ru
Is LENZ Therapeutics Inc. stock a value trapBreakout Watch & Advanced Technical Signal Analysis - mfd.ru
Is LENZ Therapeutics Inc. benefiting from interest rate changesWeekly Trading Summary & Low Risk High Win Rate Picks - mfd.ru
Guidance Update: Can LENZ Therapeutics Inc be the next market leaderEarnings Overview Summary & Low Risk Entry Point Tips - baoquankhu1.vn
Lenz Therapeutics Inc (LENZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):